Charles Wykoff, MD, PHD


Unmet Needs and the Future of Wet AMD Care

Expert panelists provide an overview of current unmet needs in wet AMD care and discuss the potential for improving clinical outcomes and treatment burden.

Clinical Trials of Alternative Targets in Wet AMD

Key opinion leaders in ophthalmology comment on the potential role of alternative targets beyond VEGF-A including VEGF-C/VEGF-D and tyrosine kinase inhibitors.

Emerging Treatments for Wet AMD

A panel of expert ophthalmologists provides insight into emerging clinical trial data on new molecules, surgical implants, and gene therapy in wet AMD.